First Time Loading...

Jenburkt Pharmaceuticals Ltd
BSE:524731

Watchlist Manager
Jenburkt Pharmaceuticals Ltd Logo
Jenburkt Pharmaceuticals Ltd
BSE:524731
Watchlist
Price: 831.6 INR 5.94% Market Closed
Updated: Jun 6, 2024
JENBURPH
/
Income Statement
/
Income from Continuing Operations

Jenburkt Pharmaceuticals Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jenburkt Pharmaceuticals Ltd
Income from Continuing Operations Peer Comparison

Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
T
TORNTPHARM

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Jenburkt Pharmaceuticals Ltd
BSE:524731
Income from Continuing Operations
₹244.5m
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
14%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
₹55.8B
CAGR 3-Years
43%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
₹41.6B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
11%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
₹90B
CAGR 3-Years
67%
CAGR 5-Years
19%
CAGR 10-Years
11%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Income from Continuing Operations
₹38.3B
CAGR 3-Years
20%
CAGR 5-Years
16%
CAGR 10-Years
16%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
₹15B
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
11%

See Also

What is Jenburkt Pharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
244.5m INR

Based on the financial report for Dec 31, 2023, Jenburkt Pharmaceuticals Ltd's Income from Continuing Operations amounts to 244.5m INR.

What is Jenburkt Pharmaceuticals Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%

Over the last year, the Income from Continuing Operations growth was 13%. The average annual Income from Continuing Operations growth rates for Jenburkt Pharmaceuticals Ltd have been 12% over the past three years , 6% over the past five years , and 14% over the past ten years .

ALPHA SPREAD
Join more than 144,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.